SRI Lanka's central bank raised interest rates for the first time in nearly three years on Thursday (19) as the rupee hit a record low amid a crippling foreign exchange shortage.
With the country of 21 million already facing shortages of imported cooking gas and sugar because of the shortage of dollars, the Central Bank of Sri Lanka increased its deposit and lending rates by 50 basis points to 5.0 per cent and 6.0 per cent respectively.
The bank said the move was to counter "imbalances" as the rupee fell against the dollar "and to preempt the buildup of any excessive inflationary pressures".
The rupee fell to 216.55 against the dollar - its lowest ever level - despite the central bank urging currency traders not to allow the local currency to fall below 202.
The government had reduced rates after the coronavirus pandemic hit last year in hope of bolstering the economy.
But Sri Lanka still recorded its worst recession in decades, with the economy shrinking 3.6 per cent as tourist arrivals collapsed and with it foreign currency receipts.
Sri Lanka's foreign reserves fell to $2.8 billion (£2b) at the end of July, from $7.5b (£5.4b) in November 2019 when the government took office.
The rupee has lost nearly 20 per cent of its value against the US dollar in that time, according to data from private banks.
Faced with currency shortages, the government banned a wide range of imports, including vehicles as well as industrial raw materials and machinery since March last year.
With supermarkets rationing staples such as sugar and milk powder, importers say they cannot get dollars at official exchange rates and have to pay black market prices.
Energy minister Udaya Gammanpila appealed to motorists this week to use fuel sparingly so that the country can use its foreign exchange to buy essential medicines and vaccines.
Another top official warned that fuel rationing may be introduced by the end of the year unless consumption was reduced.
Last month, the Moody's ratings agency placed Sri Lanka under watch for a downgrade on persistent fears that the island could default on its foreign debt.
Sri Lanka's annual foreign debt servicing is estimated at $4b to $5b (£2.9b to £3.6b) over the next four to five years, Moody's said.
The country has arranged a $250 million (£182.6m) loan from Bangladesh, and similar cash injections from India, China and South Korea.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.